Vanguard Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
Other funds holding ACAD
BBA
Vanguard Asset Management's ACAD Position: Q3 2026 in Review
Vanguard Asset Management reduced its Acadia Pharmaceuticals (ACAD) stake by 5.5% in Q3 2026, selling an estimated $181K and leaving 116,975 shares worth $2.36M. The position accounts for ﹤0.01% of the portfolio, ranked #1477.
Vanguard Asset Management first reported a position in ACAD in Q1 2026 and has held it in 3 quarters since. The position peaked at $3.13M in Q2 2026. 350 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.
- Vanguard Asset Management held 116,975 shares of Acadia Pharmaceuticals worth $2.36M as of Q3 2026.
- Vanguard Asset Management sold 6,749 Acadia Pharmaceuticals shares in Q3 2026, an estimated $181K.
- Acadia Pharmaceuticals made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #1477 holding.
- Vanguard Asset Management first reported a position in Acadia Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
- Vanguard Asset Management's Acadia Pharmaceuticals position peaked at $3.13M in Q2 2026.
- 350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.
Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.